Edwards Lifesciences Corp | 2013 | FY | 3


 

 

 
  Years Ended December 31,  
 
  2013   2012   2011  
 
  (in millions)
 

Settlements and litigation

  $ (83.6 ) $   $ 3.3  

Realignment expenses

    10.4     9.0     5.5  

IPR&D impairment

    5.9          

Licensing of intellectual property

        7.0      

European receivables reserve

            12.8  
               

Total special (gains) charges

  $ (67.3 ) $ 16.0   $ 21.6  
               
               

us-gaap:ScheduleOfUnusualOrInfrequentItemsTextBlock